NEW YORK (GenomeWeb News) – Sense Proteomic has spun out of parent firm Procognia to form a stand-alone company that will focus on using a protein array platform aimed at discovering biomarkers for cancer and auto-immune diseases.
 
The Maidenhead, UK-based company has turned to the private equity investment company Apax Partners for financial backing.
 
Financial details of the investment and the spin out were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.